Your browser doesn't support javascript.
Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics.
Schroeder, Simon; Pott, Fabian; Niemeyer, Daniela; Veith, Talitha; Richter, Anja; Muth, Doreen; Goffinet, Christine; Müller, Marcel A; Drosten, Christian.
  • Schroeder S; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Pott F; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Niemeyer D; Berlin Institute of Health, Berlin, Germany.
  • Veith T; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Richter A; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Muth D; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Goffinet C; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Müller MA; Deutsches Zentrum für Infektionsforschung, Associated Partner Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Drosten C; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Lancet Microbe ; 2(5): e210-e218, 2021 05.
Article in English | MEDLINE | ID: covidwho-1117258
ABSTRACT

BACKGROUND:

The COVID-19 agent, SARS-CoV-2, is conspecific with SARS-CoV, the causal agent of the severe acute respiratory syndrome epidemic in 2002-03. Although the viruses share a completely homologous repertoire of proteins and use the same cellular entry receptor, their transmission efficiencies and pathogenetic traits differ. We aimed to compare interferon antagonism by SARS-CoV and SARS-CoV-2.

METHODS:

For this functional study, we infected Vero E6 and Calu-3 cells with strains of SARS-CoV and SARS-CoV-2. We studied differences in cell line-specific replication (Vero E6 vs Calu-3 cells) and analysed these differences in relation to TMPRSS2-dependent cell entry based on inhibition with the drug camostat mesilate. We evaluated viral sensitivity towards type I interferon treatment and assessed cytokine induction and type I interferon signalling in the host cells by RT-PCR and analysis of transcription factor activation and nuclear translocation. Based on reverse genetic engineering of SARS-CoV, we investigated the contribution of open reading frame 6 (ORF6) to the observed phenotypic differences in interferon signalling, because ORF6 encodes an interferon signalling antagonist. We did a luciferase-based interferon-stimulated response element promotor activation assay to evaluate the antagonistic capacity of SARS-CoV-2 wild-type ORF6 constructs and three mutants (Gln51Glu, Gln56Glu, or both) that represent amino acid substitutions between SARS-CoV and SARS-CoV-2 protein 6 in the carboxy-terminal domain.

FINDINGS:

Overall, replication was higher for SARS-CoV in Vero E6 cells and for SARS-CoV-2 in Calu-3 cells. SARS-CoV-2 was reliant on TMPRSS2, found only in Calu-3 cells, for more efficient entry. SARS-CoV-2 was more sensitive to interferon treatment, less efficient in suppressing cytokine induction via IRF3 nuclear translocation, and permissive of a higher level of induction of interferon-stimulated genes MX1 and ISG56. SARS-CoV-2 ORF6 expressed in the context of a fully replicating SARS-CoV backbone suppressed MX1 gene induction, but this suppression was less efficient than that by SARS-CoV ORF6. Mutagenesis showed that charged amino acids in residues 51 and 56 shift the phenotype towards more efficient interferon antagonism, as seen in SARS-CoV.

INTERPRETATION:

SARS-CoV-2 ORF6 interferes less efficiently with human interferon induction and interferon signalling than SARS-CoV ORF6. Because of the homology of the genes, onward selection for fitness could involve functional optimisation of interferon antagonism. Charged amino acids at positions 51 and 56 in ORF6 should be monitored for potential adaptive changes.

FUNDING:

Bundesministerium für Bildung und Forschung, EU RECOVER project.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon Type I / Severe acute respiratory syndrome-related coronavirus / COVID-19 Drug Treatment Type of study: Experimental Studies Limits: Humans Language: English Journal: Lancet Microbe Year: 2021 Document Type: Article Affiliation country: S2666-5247(21)00027-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon Type I / Severe acute respiratory syndrome-related coronavirus / COVID-19 Drug Treatment Type of study: Experimental Studies Limits: Humans Language: English Journal: Lancet Microbe Year: 2021 Document Type: Article Affiliation country: S2666-5247(21)00027-6